Adenosine A2A receptor blockade prevents rotenone-induced motor impairment in a rat model of parkinsonism

Frontiers in Behavioral Neuroscience

Volumn 10, Issue FEB, 2016, Pages

  Fathalla, Ahmed M ^a   Soliman, Amira M ^a   Ali, Mohamed H ^b   Moustafa, Ahmed A ^c,d  

^a SUEZ CANAL UNIVERSITY   (Egypt)

^b Zewail City of Science and Technology   (Egypt)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d WESTERN SYDNEY UNIVERSITY   (Australia)

Author keywords

Adenosine receptors; Dopamine; Grid walk; Parkinson s disease; Rotenone; Stride length

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; DOPAMINE; ROTENONE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; FUNCTIONAL ASSESSMENT; GAIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MESENCEPHALON; MOTOR ACTIVITY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; RAT; RECEPTOR BLOCKING; TASK PERFORMANCE;

EID: 84960076511     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2016.00035     Document Type: Article

References (33)

1. Borycz, J., Pereira, M. F., Melani, A., Rodrigues, R. J., Köfalvi, A., Panlilio, L., et al. (2007). Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J. Neurochem. 101, 355-363. doi: 10.1111/j.1471-4159.2006.04386.x
2. Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., et al. (2001). Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J. Neurosci. 21: RC143.
3. Cunha, R. A., Constantino, M. D., and Ribeiro, J. A. (1997). ZM241385 is an antagonist of the facilitatory responses produced by the A2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus. Br. J. Pharmacol. 122, 1279-1284. doi: 10.1038/sj.bjp.0701507
4. Fernagut, O., Elsa, D., Bertrand, L., and Franc, T. (2002). A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 113, 123-130. doi: 10.1016/s0165-0270(01)00485-x
5. Ferreira, D. G., Batalha, V. L., Vicente Miranda, H., Coelho, J. E., Gomes, R., Gonçalves, F. Q., et al. (2015). Adenosine A2A receptors modulate α-synuclein aggregation and toxicity. Cereb. Cortex bhv 268. doi: 10.1093/cercor/bhv268 [Epub ahead of print].
6. Flecknell, P. A. (1993). Anesthesia of animals for biomedical research. Br. J. Anaesth. 71, 885-894. doi: 10.1093/bja/71.6.885
7. Fredholm, B. (2010). Adenosine receptors as drug targets. Exp. Cell Res. 316, 1284-1288. doi: 10.1016/j.yexcr.2010.02.004
8. Gomes, C. A., Simões, P. F., Canas, P. M., Quiroz, C., Sebastião, A. M., Ferré, S., et al. (2009). GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A2A receptors. J. Neurochem. 108, 1208-1219. doi: 10.1111/j.1471-4159.2009.05876.x
9. Gyoneva, S., Shapiro, L., Lazo, C., Garnier-Amblard, E., Smith, Y., Miller, G. W., et al. (2014). Adenosine A2A receptor antagonism reverses inflammationinduced impairment of microglial process extension in a model of Parkinson’s disease. Neurobiol. Dis. 67, 191-202. doi: 10.1016/j.nbd.2014.03.004
10. Higley, M. J., and Sabatini, B. L. (2010). Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat. Neurosci. 13, 958-966. doi: 10.1038/nn.2592
11. Hisahara, S., and Shimohama, S. (2010). Toxin-induced and genetic animal models of Parkinson’s disease. Parkinsons Dis. 2011:951709. doi: 10.4061/2011/951709
12. Höglinger, G. U., Féger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., et al. (2003). Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502. doi: 10.1046/j.1471-4159.2003.01533.x
13. Hussein, J., Abo El-Matty, D., El-Khayat, Z., and Abdel-Lativ, Y. (2012). Brain neurotransmitters in diabetic rats treated with coenzyme Q10. Int. J. Pharm. Pharm. Sci. 4, 554-556.
14. Jenner, P. (2014). An overview of adenosine A2A receptor antagonists in Parkinson’s disease. Int. Rev. Neurobiol. 119, 71-86. doi: 10.1016/b978-0-12-801022-8.00003-9
15. Kramberger, M., Stukovnik, V., Cus, A., Repovs, G., Tomse, P., Meglic, N., et al. (2010). Parkinson’s disease dementia: clinical correlates of brain spect perfusion and treatment. Psychiatr. Danub. 22, 446-449.
16. Li, C., Chen, X., Zhang, N., Song, Y., and Mu, Y. (2012). Gastrodin inhibits neuroinflammation in rotenone-induced Parkinson’s disease model rats. Neural Regen. Res. 7, 325-331. doi: 10.3969/j.issn.1673-5374.2012.05.001
17. Liu, B. (2006). Modulation of microglia pro-inflammatory and neurotoxic activity for the treatment of Parkinson’s disease. AAPS J. 8, E606-E621. doi: 10.1208/aapsj080369
18. Matos, M., Shen, H. Y., Augusto, E., Wang, Y., Wei, C. J., Wang, Y. T., et al. (2015). Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia. Biol. Psychiatry 78, 763-774. doi: 10.1016/j.biopsych.2015.02.026
19. Menet, V., Prieto, M., Privat, A., and Giménez M. y Ribotta, M. (2003). Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc. Natl. Acad. Sci. USA100,8999-9004.doi:10.1073/pnas.1533187100
20. Morelli, M., Di Paolo, T., Wardas, J., Calon, F., Xiao, D., and Schwarzschild, M. A. (2007). Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 83, 293-309. doi: 10.1016/j.pneurobio.2007.07.001
21. Moustafa, A. A., Krishna, R., Frank, M. J., Eissa, A. M., and Hewedi, D. H. (2014). Cognitive correlates of psychosis in patients with Parkinson’s disease. Cogn. Neuropsychiatry 19, 381-398. doi: 10.1080/13546805.2013.877385
22. Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., and Damier, P. (2004). Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord. 19, 997-1005. doi: 10.1002/mds.20243
23. Pinna, A., Bonaventura, J., Farré, D., Sánchez, M., Simola, N., Mallol, J., et al. (2014). L-DOPA disrupts adenosine A2A-cannabinoid CB1 dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp. Neurol. 253, 180-191. doi: 10.1016/j.expneurol.2013.12.021
24. Quiroz, C., Luján, R., Uchigashima, M., Simoes, A. P., Lerner, T. N., Borycz, J., et al. (2009). Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 9, 1321-1344. doi: 10.1100/tsw.2009.143
25. Samim, M., Yajamanam, S. H., Bano, N., Veeresh, B., and Reddy, M. B. (2014). Neuroprotective effect of ocimum sanctum linn on rotenone induced Parkinsonism in rats. IJPRS 3, 772-784.
26. Schiffmann, S. N., Fisone, G., Moresco, R., Cunha, R. A., and Ferré, S. (2007). Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 83, 277-292. doi: 10.1016/j.pneurobio.2007.05.001
27. Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J. F., and Morelli, M. (2006). Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 29, 647-654. doi: 10.1016/j.tins.2006.09.004
28. Sharma, N., and Nehru, B. (2013). Beneficial effect of vitamin E in rotenone induced model of PD: behavioral, neurochemical and biochemical study. Exp. Neurobiol. 22, 214-223. doi: 10.5607/en.2013.22.3.214
29. Shen, H. Y., Canas, P. M., Garcia-Sanz, P., Lan, J. Q., Boison, D., Moratalla, R., et al. (2013). Adenosine A2A receptors in striatal glutamatergic terminals and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One 8:e80902. doi: 10.1371/journal.pone.0080902
30. Silva, C. G., Porciúncula, L. O., Canas, P. M., Oliveira, C. R., and Cunha, R. A. (2007). Blockade of adenosine A2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol. Dis. 27, 182-189. doi: 10.1016/j.nbd.2007.04.018
31. Thiffault, C., Langston, J., and Di Monte, D. (2000). Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 885, 283-288. doi: 10.1016/s0006-8993(00)02960-7
32. von Wrangel, C., Schwabe, K., John, N., Krauss, J. K., and Alam, M. (2015). The rotenone-induced rat model of Parkinson’s disease: behavioral and electrophysiological findings. Behav. Brain Res. 279, 52-61. doi: 10.1016/j.bbr.2014.11.002
33. Zaitone, S. A., Abo-Elmatty, D. M., and Elshazly, S. M. (2012). Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J. Pharmacol. 44, 774-779. doi: 10.4103/0253-7613.103300